Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.
Type:
Grant
Filed:
June 5, 2009
Date of Patent:
August 27, 2013
Assignee:
Teknologian Tutkimuskeskus VTT
Inventors:
Kristiina Takkinen, Hans Söderlund, Timo Pulli
Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
Type:
Grant
Filed:
May 8, 2007
Date of Patent:
August 20, 2013
Assignee:
Creagene Inc.
Inventors:
Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
Type:
Grant
Filed:
January 23, 2008
Date of Patent:
August 6, 2013
Assignee:
University College Cardiff Consultants Limited
Inventors:
Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
Type:
Grant
Filed:
January 24, 2011
Date of Patent:
July 9, 2013
Assignee:
Stichting Voor de Technische Wetenshappen
Inventors:
Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.
Type:
Grant
Filed:
June 5, 2009
Date of Patent:
July 2, 2013
Assignee:
Teknologian Tutkimuskeskus VTT
Inventors:
Kristiina Takkinen, Hans Söderlund, Timo Pulli
Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.
Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.
Type:
Grant
Filed:
March 30, 2009
Date of Patent:
March 19, 2013
Assignee:
Prince Henry's Institute of Medical Research
Inventors:
David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.
Abstract: Disclosed are an antigen protein of black-lip pearl oyster egg extract, an antibody specific thereto, and a method of quantitative assessment of the reproductive effort of black-lip pearl oyster using the antibody. The method accomplishes quantitative assessment of reproductive effort of black-lip pearl oysters easily and accurately. In addition, the method provides important information for the study of life cycles of black-lip pearl oysters, and allows efficient management of black-lip pearl oysters.
Type:
Grant
Filed:
April 13, 2010
Date of Patent:
February 5, 2013
Assignee:
Korea Ocean Research And Development Institute
Inventors:
Do Hyung Kang, Kwang Sik Choi, Hee Do Jeoung, Heung Sik Park
Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.
Type:
Grant
Filed:
August 15, 2007
Date of Patent:
February 5, 2013
Assignee:
Beijing Cotimes Biotech Co., Ltd.
Inventors:
Enyun Shen, Zheng Yu, Min Zhou, Fei Guo
Abstract: The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (?2-GPI) as an indicator for atherosclerosis.
Type:
Grant
Filed:
June 4, 2010
Date of Patent:
December 25, 2012
Assignee:
Inova Diagnostics, Inc.
Inventors:
G. Michael Iverson, Walter L. Binder, Gary L. Norman
Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
Type:
Grant
Filed:
August 25, 2008
Date of Patent:
November 13, 2012
Assignees:
Van Andel Research Institute, Fred Hutchinson Cancer Research Center
Inventors:
Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
Abstract: Disclosed is an isolated polynucleotide encoding a modified Fab' antibody, which includes an Fd chain and an L chain with the Fd chain including a CH1 region and the L chain including a CL region, wherein the modified Fab' antibody further includes a cysteine for binding to a fluorescent dye, and the polynucleotide includes an Fd chain coding region and an L chain coding region linked therebetween in a manner that will allow expression of the modified Fab' antibody. Also disclosed are an expression vector containin the isolated polynucleotide, an isolated transformed host cell containing the expression vector, and a cell culture including the transformed host cell.
Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.
Type:
Grant
Filed:
October 28, 2008
Date of Patent:
October 9, 2012
Assignee:
Assistance Publique-Hopitaux de Paris
Inventors:
Didier Payen De La Garanderie, Anne-Claire Lukaszewicz
Abstract: By detecting an antibody which immunologically reacts with amylase ?2-A in a sample, AIP or FT1DM is examined or the possibility of developing FT1DM is determined. For instance, detection of this antibody is carried out by an immunological method using an antigen which immunologically reacts with this antibody. The antigen is preferably a partial fragment containing the amino acid sequence of amino acid numbers 299 to 511 of human amylase ?2-A (SEQ ID NO: 1).
Type:
Grant
Filed:
May 2, 2008
Date of Patent:
October 2, 2012
Assignees:
University of Yamanashi, Cosmic Corporation
Abstract: The present invention relates to antibodies, binding portions thereof, or probes that bind specifically to glucosyltransferase enzymes, and uses of these agents for detecting glucosyltransferase enzyme(s) in a sample and for diagnosing predisposition of a human child to early childhood caries. The present invention also relates to a kit for detecting a glucosyltransferase enzyme in an oral sample from an animal.
Type:
Grant
Filed:
August 14, 2006
Date of Patent:
September 11, 2012
Assignee:
University of Rochester
Inventors:
William H. Bowen, Anne Vacca Smith, Robert Berkowitz
Abstract: The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications.
Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.
Abstract: A method of in situ immunohistochemical analysis of a biological sample is provided. The method allows for the multiplex and simultaneous detection of multiple antigens, including multiple nuclear antigens, in a tissue sample.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
January 10, 2012
Assignee:
Aureon Laboratories, Inc.
Inventors:
Stefan Hamann, Michael Donovan, Mark Clayton, Angeliki Kotsianti